Form 4: Cryo-Cell Co-CEO Portnoy Boosts Stake

Cryo-Cell International Inc.'s Chairman and Co-CEO, David Portnoy, reported significant open market purchases of common stock, increasing his beneficial ownership.

Summary

• David Portnoy, Chairman, Co-CEO, Director, and 10% Owner of Cryo-Cell International Inc. (CCEL), acquired 19,201 shares of common stock through open market purchases.
• On August 15, 2025, Portnoy purchased 2,671 shares at a weighted average price of $4.50 and 6,418 shares at a weighted average price of $4.43.
• On August 18, 2025, an additional 9,327 shares were acquired at a weighted average price of $4.37.
• On August 19, 2025, 885 shares were purchased at $4.37.
• Following these transactions, Portnoy's direct beneficial ownership stands at 804,742 shares of common stock.
• Indirect beneficial ownership includes 135,721 shares via 401K, 237,039 shares via IRA, 102,586 shares by spouse, 152,882 shares by Mayim Limited Partnership, 59,027 shares by LLC, 55,219 shares by uTIPu, Inc., and 37,746 shares as custodian for his children.
• Portnoy also holds various stock options, including 280,000 options with a strike price of $12.27 that vest immediately if the company's common stock reaches $25.00 per share.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to substantial open market purchases by a key insider, indicating strong confidence in the company's future performance and valuation.

Positives

• Significant insider buying by a key executive (Chairman, Co-CEO, and 10% Owner) signals strong confidence in the company's future prospects.
• The purchases were made at varying price points between $4.37 and $4.50, indicating a belief in value at current levels.
• The accumulation of shares across various accounts (direct, 401K, IRA, corporate entities, and custodial accounts) demonstrates a broad commitment to increasing ownership.

Risks

• The vesting of 280,000 stock options is contingent on the company's common stock reaching $25.00 per share, which represents a substantial increase from the purchase prices and current levels, indicating a high performance hurdle for full vesting.

Future Outlook

NA

Industry Context

This filing, a Form 4, reports insider trading activity and does not provide broader industry context. However, insider purchases in the biotechnology and healthcare sectors, where Cryo-Cell International operates, can signal management's confidence in future growth or specific product developments within a dynamic and often capital-intensive industry.

Comparison to Industry Standards

• NA

Related Party Transactions

• David Portnoy's beneficial ownership includes shares held by Mayim Limited Partnership (152,882 shares), where he is deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership.
• David Portnoy's beneficial ownership also includes shares held by uTIPu, Inc. (55,219 shares), where he is deemed the beneficial owner as the Chairman of the Board and Secretary.

Stakeholder Impact

• Shareholders may view the insider purchases as a positive indicator of future stock performance and management alignment with shareholder interests.
• The increased ownership by a key executive could reinforce confidence among employees and partners regarding the company's stability and strategic direction.

Key Dates

Recommendation

The significant open market purchases by the Chairman and Co-CEO, who is also a 10% owner, at prices ranging from $4.37 to $4.50, strongly signal management's conviction in the company's intrinsic value and future growth potential. This insider buying, especially from a high-level executive, is a powerful bullish indicator that often precedes positive price movements, making it a 'strong buy' signal for investors.

Keywords

Cryo-Cell International, CCEL, Insider Buying, Stock Purchase, Form 4, David Portnoy, Beneficial Ownership, Stock Options, Biotechnology, Healthcare